AstraZeneca opened a new corporate office in Mumbai, in western India, on October 16, 2026, according to a stock exchange filing by AstraZeneca Pharma India, the company’s India unit. Devendra Fadnavis, Chief Minister of the state of Maharashtra, inaugurated the 25,600-square-foot office.
The office will house the company’s commercial operations, site management and monitoring, technology, research and development, and global business services teams.
Fadnavis praised the state’s drug and life sciences sector at the opening. “Maharashtra has a strong and growing pharmaceutical and life sciences ecosystem,” he said, according to the filing.
AstraZeneca’s Academy House office in Cambridge, UK. Photo: D Wells, CC BY-SA 4.0, via Wikimedia Commons
Praveen Rao Akkinepally, country president and managing director of AstraZeneca India, said: “India is at an important inflection point in healthcare.” He stressed stronger partnerships and access to therapies.
The company gave this picture of its India business:
- It has introduced more than twenty-five new drugs and indications in India over the past three years.
- Approximately eighty global clinical trials are running in India.
- Its work in India covers oncology, biopharmaceuticals and rare diseases.
The company also said it is pursuing artificial intelligence-based solutions and new access pathways across prevention, awareness, diagnosis and treatment.
AstraZeneca has its corporate headquarters in Cambridge, UK. According to its website, it employs 96,100 people worldwide and reported revenue of $58.7 billion in 2025.
Why this matters: AstraZeneca has placed commercial, research, technology and global business services teams in one new office in Mumbai. American and European pharmaceutical companies weighing India can note that a company with $58.7 billion in revenue is building that mix in the country.
